GHK-Cu Dosage Calculator

How GHK-Cu Dosage Calculation Works

The GHK Cu dosage calculator on this page converts your daily mg dose to syringe units and injection volume for U-100 or U-40 syringes. GHK-Cu (copper peptide) is dosed in milligrams per injection — typically 1–2 mg daily — and requires knowing your vial concentration to draw accurately.

1. Concentration (mcg/mL) = Vial size (mg) × 1,000 ÷ BAC water added (mL)
2. Units to draw = (Target dose in mcg ÷ Concentration) × 100 for U-100 syringe

Example: 50 mg vial + 3 mL BAC water = 16,667 mcg/mL. A 1 mg (1,000 mcg) dose = 1,000 ÷ 16,667 × 100 ≈ 6 units on U-100 (0.06 mL). A 2 mg dose ≈ 12 units. Enter your values above and the calculator handles the math.

GHK-Cu Dose Reference — U-100 Syringe Units

Common GHK-Cu doses and syringe units at 16,667 mcg/mL (50 mg vial + 3 mL BAC water):

• 1 mg (1,000 mcg): 6 units on U-100 — 0.06 mL
• 1.5 mg (1,500 mcg): 9 units on U-100 — 0.09 mL
• 2 mg (2,000 mcg): 12 units on U-100 — 0.12 mL

At 16,667 mcg/mL, draws are small (6–12 units). For more readable unit marks, use 10 mL BAC water (5,000 mcg/mL), which gives 20–40 units for typical doses. Use the peptide reconstitution calculator to model different vial sizes or BAC water volumes for multi-week supply planning.

GHK-Cu Vial Sizes: 50 mg vs. 100 mg

GHK-Cu is typically sold in 50 mg or 100 mg bulk vials — it is a cheaper peptide than most, so small 5–10 mg vials are uncommon. Common reconstitution options for a 50 mg vial:

• 50 mg vial + 3 mL BAC water: 16,667 mcg/mL — 28-day supply at 1 mg/day uses 1.7 mL. Very concentrated; small draws.
• 50 mg vial + 10 mL BAC water: 5,000 mcg/mL — 1 mg dose = 20 units (0.20 mL); 2 mg = 40 units. More readable unit marks.
• 100 mg vial + 20 mL BAC water: 5,000 mcg/mL — same concentration as above, double the total volume. Use 5.6 mL over 28 days; discard or transfer the rest to a sterile vial.

Because reconstituted peptide should be used within 28 days, plan your BAC water volume based on how much you use per cycle. At 1 mg/day with 3 mL BAC water, you use the vial comfortably within 28 days.

Subcutaneous vs. Topical GHK-Cu

GHK-Cu is most commonly discussed in topical forms (creams, serums, microneedling solutions) for skin repair and hair growth. Subcutaneous injection delivers GHK-Cu systemically rather than locally. Research on the subcutaneous route is limited compared to topical applications, but the biohacking community commonly uses 1–2 mg/day subcutaneous for systemic effects. Both routes require accurate dosing; this calculator is designed for subcutaneous injection.

Stacking GHK-Cu with BPC-157 and TB-500

GHK-Cu is frequently combined with BPC-157 and TB-500 in regenerative peptide stacks. All three have distinct mechanisms: BPC-157 promotes angiogenesis and growth factor upregulation; TB-500 (Thymosin Beta-4) promotes cell migration and actin polymerization; GHK-Cu activates gene expression pathways linked to tissue repair and antioxidant defense. Because BPC-157 is dosed in micrograms while GHK-Cu and TB-500 are dosed in milligrams, each is typically injected separately. See the BPC-157 dosage calculator and TB-500 dosage calculator.

GHK-Cu Benefits and Research

GHK-Cu (glycyl-l-histidyl-l-lysine copper) is a naturally occurring tripeptide that binds copper and is found in human plasma, saliva, and urine. Research by Loren Pickart and others identified GHK-Cu as a potent modulator of gene expression: it activates approximately 31 genes related to tissue remodeling, antioxidant defense, and anti-inflammatory signaling, while down-regulating overactive inflammatory genes. Its plasma concentration declines sharply with age — approximately 200 ng/mL at age 20, falling to roughly 80 pg/mL by age 60, a ~1,000-fold drop that has positioned it as a longevity target.

In vitro and animal research supports GHK-Cu's role in wound healing (increased collagen and elastin synthesis, accelerated wound closure), skin regeneration (stimulation of keratinocyte migration and dermal fibroblast activity), hair follicle stimulation (studied in androgenic alopecia models), nerve regeneration (improved neurite outgrowth in animal models), and antioxidant defense (upregulation of superoxide dismutase and other antioxidant enzymes). Clinical evidence in humans is primarily topical — several controlled trials show statistically significant improvements in skin firmness, thickness, and fine lines with topical GHK-Cu serums. Subcutaneous injection research is limited and largely self-reported.

• Collagen and elastin synthesis: upregulates fibronectin and collagen-related gene expression in fibroblasts
• Wound healing: accelerated wound closure and re-epithelialization in animal models
• Antioxidant defense: induces superoxide dismutase and other antioxidant pathways
• Hair follicle stimulation: studied in alopecia models; topical clinical trials show modest but statistically significant improvement
• Nerve regeneration: improved neurite outgrowth in animal studies; potential neuroprotective applications
• Age-related decline: plasma GHK-Cu falls ~1,000× between ages 20 and 60 — exogenous supplementation targets this deficit

GHK-Cu is frequently combined with BPC-157 and TB-500 in regenerative stacks. See the BPC-157 dosage calculator and TB-500 dosage calculator for dosing details on companion peptides.

GHK-Cu Side Effects and Safety

GHK-Cu has one of the most favorable safety profiles among research peptides. It is endogenously produced in the human body, and its copper-binding activity is tightly regulated by the body's copper homeostasis mechanisms. Both topical and subcutaneous use are generally considered very safe at research doses.

• Topical irritation — occasional mild redness or irritation with high-concentration topical formulations; uncommon at standard concentrations
• Injection site reactions — minor discomfort or erythema at the injection site; self-reported as mild and transient
• Copper excess (theoretical) — at very high doses, excess copper could theoretically cause toxicity (nausea, hepatic effects); not documented at typical research doses of 1–2 mg/day, far below known toxic copper thresholds
• Unknown long-term subcutaneous effects — no long-term human injection studies exist; safety extrapolated from topical clinical data and animal research

No significant adverse events have been established in the published literature for GHK-Cu at research doses. It is not FDA-approved for injectable use. Use only under the supervision of a licensed healthcare provider, who can assess individual copper metabolism status and monitor for unexpected reactions.

Storage and Safe Handling

Refrigerate reconstituted GHK-Cu at 2–8°C and use within 28 days. Lyophilized GHK-Cu powder is relatively stable at room temperature, but store away from moisture and light for best longevity. Always use aseptic technique: wipe the vial stopper with an alcohol swab before each draw and use a fresh needle per injection. Dispose of sharps in a puncture-resistant container.